Pacific Edge Limited Level 1, 18 Filleul Street, Dunedin 9016, New Zealand Pacific Edge Limited (NZX/ ASX: PEB) has reported financial and operational results for the year to 31 March 2022, showing strong growth in the adoption of its advanced genomic biomarker Cxbladder tests.

Total operating revenue increased 49% to $11.4 million, while total revenue increased 33% to $13.9 million.

Net losses after tax increased to $19.8 million from $14.2 million, reflecting a 37% increase in operating expenses to $33.7 million as the company invested to drive growth.

Pacific Edge is well funded with cash and cash equivalents and short-term deposits at $105.4 million at the end of the financial year, following the successful $103.5 million capital raise and dual listing on the ASX in 2021.

The company has announced initiatives of the Investment Program to drive customer retention, growth, and clinical evidence generation relevant to guideline inclusion.

See more